Janssen Publishes First Annual Price Transparency Report

Janssen published the first of its annual drug price transparency reports, stating the average net price of its products rose 3.5 percent in 2016, after discounts and rebates — slower than the 5.2 percent increase seen the year before, and under the rate of medical inflation.

The Johnson & Johnson subsidiary said the average list price increased by 8.5 percent last year, but that the company offered approximately $11 billion in U.S. rebates, resulting in a discount rate of 35.2 percent. Meanwhile, medical inflation increased by 4.1 percent in 2016, according to the report.